Drugs / TG100801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00414999 | Nov 2006 → Feb 2007 | diabetic retinopathy, macular degeneration | TargeGen | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00509548 | Jul 2007 → Mar 2008 | choroidal neovascularization, macular degeneration | TargeGen | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TG100801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00414999 ↗ |
| Action | Inhibit | “TG100801 is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies” NCT00414999 ↗6“Vascular endothelial growth factor receptor 1 inhibitor” CHEMBL403989 ↗ “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL403989 ↗ “Platelet-derived growth factor receptor beta inhibitor” CHEMBL403989 ↗ “Fibroblast growth factor receptor 2 inhibitor” CHEMBL403989 ↗ “Fibroblast growth factor receptor 1 inhibitor” CHEMBL403989 ↗ “Ephrin type-B receptor 4 inhibitor” CHEMBL403989 ↗ |
| Modality | Small molecule | — CHEMBL403989 ↗ |
| Route | Topical | “TG100801 Eye Drops” NCT00414999 ↗ |
| Target | EPHB4 | “Ephrin type-B receptor 4 inhibitor” CHEMBL403989 ↗ |
| Target | FGFR1 | “Fibroblast growth factor receptor 1 inhibitor” CHEMBL403989 ↗ |
| Target | FGFR2 | “Fibroblast growth factor receptor 2 inhibitor” CHEMBL403989 ↗ |
| Target | FLT1 | “Vascular endothelial growth factor receptor 1 inhibitor” CHEMBL403989 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL403989 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL403989 ↗ |